Product Information

LYRICA 200 MG CAPSULE is a brand product labeled by Pfizer Inc., priced at $9.6932 per EA under NDC 00071101768. Its NADAC has been published 662 times since Nov 28, 2013.

FDA first approved this application on Dec 30, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the PREGABALIN market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

LYRICA 200 MG CAPSULE

PREGABALIN
$9.6932per EA
Discontinued
High Outlier
DEA Schedule CV

Strength

200 mg/1

Manufacturer

Pfizer Inc.

NDC

00071101768

Classification

Brand

Dosage Form

CAPSULE

Route

ORAL

Effective Date

7/22/2026

Active Ingredients

PREGABALIN

Approval Type

New Drug (NDA)

FDA Application

NDA021446

FDA Approved

12/30/2004

TE Code

AB

On Market Since

12/30/2004

Price Statistics

The NADAC for LYRICA 200 MG CAPSULE has been published 662 times since Nov 28, 2013, and over the history we have for it it has risen 170.0%. The table below summarizes its recorded NADAC range and movement.

Current price$9.6932 per EA
All-time high$9.7100 (Nov 12, 2025)
All-time low$3.5902 (Nov 28, 2013)
52-week high$9.7100
52-week low$9.6932
Median price$7.8311
Average price$7.4763
Largest weekly change+9.4% (Jan 4, 2017)
Weeks tracked662
Tracking sinceNov 28, 2013

Price History

1W

N/A

1M

-0.0%

3M

-0.0%

6M

-0.1%

1Y

-0.1%

3Y

+5.2%

5Y

+17.6%

All

+170.0%

Last surveyed Jul 29, 2026 — this NDC no longer appears in the current weekly NADAC file.

Generic Alternatives

The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Related Drugs

Same classification

No related drugs found.

Frequently asked questions

What is the NADAC price of LYRICA 200 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for LYRICA 200 MG CAPSULE, manufactured by Pfizer Inc., is $9.6932 per EA (NDC 00071101768), effective Jul 29, 2026.

How has the price of LYRICA 200 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for LYRICA 200 MG CAPSULE has risen 170.0%. It has been tracked across 662 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for LYRICA 200 MG CAPSULE?

Since Nov 28, 2013, the NADAC for LYRICA 200 MG CAPSULE has ranged from a low of $3.5902 (Nov 28, 2013) to a high of $9.7100 (Nov 12, 2025), with a median of $7.8311 per EA.

Are there cheaper alternatives to LYRICA 200 MG CAPSULE?

Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PREGABALIN 200 MG CAPSULE, is $0.0566 per EA — about 99% below LYRICA 200 MG CAPSULE.

Who manufactures LYRICA 200 MG CAPSULE?

LYRICA 200 MG CAPSULE (NDC 00071101768) is labeled by Pfizer Inc., and CMS classifies it as a brand product.